Market Cap | 1.94M | P/E | 0.00 | EPS this Y | - | Ern Qtrly Grth | - |
Income | - | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 7.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -54.00% |
Dividend | N/A | Price/Book | EPS next 5Y | - | 52W High Chg | -93.00% | |
Recommedations | - | Quick Ratio | - | Shares Outstanding | 8.79B | 52W Low Chg | 400.00% |
Insider Own | - | ROA | - | Shares Float | - | Beta | - |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00100 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 3,944,024 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 3,846,238 | Change | 0.00% |
ProText Mobility, Inc., a biotech company, engages in the development of pharmaceutical botanical medicines. Its medicines are formulated with highly-bioavailable plant extracts. The company is based in Fort Lauderdale, Florida. ProText Mobility, Inc. operates as a subsidiary of Plandaí Biotechnology, Inc.